Finding the 'fingerprints' of prostate cancer

November 23, 2010 by Tom Vasich
“We’re aiming to meet a critical unmet need in prostate cancer treatment,” says Dr. Dan Mercola, who has developed biomarker tests to enhance diagnosis and prognosis. Behind him is a dramatically enlarged image of biopsy tissue. Photo: Steve Zylius

( -- Dr. Dan Mercola has identified genetic biomarkers -- or 'fingerprints' -- of prostate cancer that yield specific information about tumors, permitting earlier detection and more effective treatment.

Like many middle-aged men, Dr. Dan Mercola thinks a lot about .

But the UC Irvine professor of pathology & laboratory medicine has no personal concerns. Instead, he’s using his considerable research skills to help the more than 200,000 men diagnosed with the disease each year in the U.S.

Mercola hopes to do this by making it easier for physicians to diagnose and gauge the severity of prostate cancer, which affects nearly one in five American men during their lifetime. He has identified genetic biomarkers — or “fingerprints” — of the disease that yield specific information about prostate tumors, permitting earlier detection and more effective treatment.

To accelerate the transformation of his findings into clinical products, Mercola and UCI colleague Michael McClelland established the startup biotech company Proveri Inc., which licenses his UC-patented and -owned technology to develop diagnostic and prognostic tests for prostate cancer.

“As a physician and a researcher, you feel you’ve accomplished something if your discoveries help people,” says Mercola, co-leader of the Prostate Translational Working Group at UCI’s Chao Family Comprehensive Cancer Center. “I believe that to fulfill your promise, you need to pursue these opportunities.”

Prostate cancer is the most common malignancy among American men. It can be either aggressive, which requires radical treatment, or indolent, requiring only conservative medical management. However, it’s not always possible at the time of diagnosis to tell which form a patient has.

Mercola’s work on biomarkers began in the late 1990s, when he led a multisite study in San Diego to find the genes expressed in the four major cell types within prostate carcinoma. More than 3,200 genes predominantly expressed in at least one of these cell types were identified.

Using this array of genes, Mercola created a biomarker test for prostate cancer that renders a prognosis at the same time as diagnosis. Knowing whether they have the aggressive or indolent version, he says, lets patients better understand their disease and treatment options.

To test this method, Mercola in 2005 began a National Cancer Institute-sponsored group — SPECS — that recruited more than 1,500 patients from seven sites in Southern California and at Northwestern University in Chicago. With results from this trial, Mercola — through Proveri − and partner AltheaDx are developing an RNA-based assay test for use by oncologists.

“We’re aiming to meet a critical unmet need in prostate cancer treatment,” Mercola says. “Up to 30 percent of men don’t need radical treatments like radiation or surgery, and this test will allow us to determine who they are.”

Earlier this year, he received a second $3.5 million NCI grant as part of the agency’s Early Detection Research Network to develop another test – this one to enhance the results of prostate biopsies.

More than 1 million such biopsies are performed in the U.S. annually, and 10 percent to 15 percent are found to be “nondiagnostic,” Mercola says. These don’t contain tumor cells but exhibit other abnormalities, requiring the patient to return for another biopsy within a year.

His diagnostic test can detect the presence of tumor cells elsewhere in the prostate through unusual gene activity in “nondiagnostic” biopsy tissue.
Currently, Mercola is collaborating with UCI urologist Dr. Atreya Dash and Orange County Urology Associates to enroll 900 men scheduled to undergo prostate biopsies in a clinical trial of the test’s effectiveness.

With results from this trial, he will work — again through Proveri — to bring to the clinic a tissue-based assay that will let pathologists use digital microscopic imaging of to diagnose formerly “nondiagnostic” cases.

“A test like this is badly needed,” Mercola says. “It reveals tumors six months to a year sooner, lets us identify who needs a repeat biopsy as soon as possible and provides new treatment choices for those now in diagnostic limbo. Early detection holds great promise for better prostate cancer outcomes.”

More information:

Related Stories

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.